{
  "id": 12949259,
  "title": "Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting",
  "url": "https://urgent.news/2026/10/08/spruce-biosciences-announces-presentation-of-mps-iiib-natural-history",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T20:08:48.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/spruce-biosciences-announces-presentation-of-mps-iiib-natural-history-data-at-the-55th-child-neurology-society-annual-meeting"
  },
  "original_language": "en",
  "account": null,
  "summary": "SOUTH SAN FRANCISCO, Calif. — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Financial Post",
        "title": "AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting",
        "url": "https://urgent.news/2026/10/08/abcellera-announces-presentation-of-phase-1-2-data-for-abcl635-at-tms",
        "published": "2026-10-08T20:08:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}